publication date: May. 2, 2016

NCI CTEP-Approved Trials for the Month of April

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9771: Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors. National Cancer Institute Developmental Therapeutics Clinic; Chen, A. P. (301) 496-4291

 

9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor. City of Hope Comprehensive Cancer Center LAO; Riess, Jonathan W. (916) 734-3772

 

9903: A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor. Dana-Farber – Harvard Cancer Center LAO; Oxnard, Geoffrey Raymond. (617) 632-6049

 

Phase II

ALTE1621: Pharmacologic … Continue reading CCL April – NCI CTEP-Approved Trials for the Month of April

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.